Daiichi Sankyo announced that it has received approval for its oncolytic virus G47 (trade name: DELYTACT). The approval is primarily based on the Japan Ph2 research (investigator led-study) findings led by Dr. Todo of the Institute of Medical Science, The University of Tokyo undertaken in patients with residual or recurrent glioblastoma.
TILT Biotherapeutics Ltd. partnered with Biotheus Inc. to promote the global development and marketing of TILT-123, a cancer treatment product, and also make it available to Chinese cancer patients. Further, the agreement involves a down payment as well as payments at specified points in the clinical research process and is qualified to collect large royalties on future sales payments.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 2988
Published Date: Jul 27, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing prevalence of cancer globally and the growing advancements in viral engineering are the major factors driving the growth of the market.
The market size of oncolytic virus therapy is anticipated to attain a CAGR of 27% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Shanghai Sunway Biotech Co. Ltd., Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus Inc., TAKARA BIO INC., Vyriad, Transgene SA, Lokon Pharma AB, Pfizer Inc., Rigvir Group, Sibiono GeneTech Co. Ltd.
The HSV-based segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.